Mrs. Lisa Wang has been the sole Biostatistician for the Princess Margaret Hospital Consortium (PMHC) over the past 11 years, which has led more than 100 early-phase academic trials in Canada. Many of these studies incorporate novel endpoints, designs, assessment and validation of innovative therapeutic strategies for cancer, including molecular targeted therapies. She was the Chair of Data Safety Monitor Board (DSMB) of PMHC from 2007-2016 and a member of the PMCC DSMB from 2007-2013. Her primary research interests are early-phase clinical trial design, time-to-event analysis, longitudinal and missing data analysis. She is a first and co-author of more than 100 publications, in major statistical, medical research book chapters and journals.